RESUMEN
AIMS/HYPOTHESIS: We studied fetal and childhood growth patterns that are associated with IGT and type 2 diabetes in adult life. METHODS: We examined clinically 2,003 subjects born in Helsinki between 1934 and 1944. They had on average 11 measurements of height and weight between birth and 2 years of age, and seven measurements between 2 and 11 years of age. Glucose tolerance in adult life was assessed by a 75-g oral glucose tolerance test. RESULTS: We identified 311 subjects with type 2 diabetes and 496 with IGT. Both IGT and type 2 diabetes were associated with low birthweight (p < 0.0001 adjusting for current BMI). The risk of these conditions was increased by low weight gain between birth and 2 years. A 1 SD increase in weight at 2 years was associated with an odds ratio for either type 2 diabetes or IGT of 0.76 (95% CI 0.69-0.84). This effect was greatest in people who had low birthweight. Low growth in the first 6 months after birth was a critical period for the development of insulin resistance in later life; other critical periods were associated with slow fetal growth and rapid increase in BMI between age 2 and 11 years. CONCLUSIONS/INTERPRETATION: Low weight gain during infancy increases the risk of IGT and type 2 diabetes. The effect is greater in people who had low birthweight. The first 6 months after birth may be the most critical period for growth, in relation to development of glucose intolerance.
Asunto(s)
Índice de Masa Corporal , Diabetes Mellitus Tipo 2/epidemiología , Crecimiento/fisiología , Aumento de Peso/fisiología , Anciano , Envejecimiento/fisiología , Peso al Nacer , Glucemia/metabolismo , Peso Corporal , Niño , Finlandia/epidemiología , Intolerancia a la Glucosa/epidemiología , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/sangre , Persona de Mediana Edad , Factores de RiesgoRESUMEN
A possible relationship between the pathogenesis of type 2 diabetes and coenzyme Q10 (CoQ10) deficiency has been proposed. The aim of this study was to assess the effect of CoQ10 on metabolic control in 23 type 2 diabetic patients in a randomized, placebo-controlled trial. Treatment with CoQ10 100 mg bid caused a more than 3-fold rise in serum CoQ10 concentration (p < 0.001). No correlation was observed between serum CoQ10 concentration and metabolic control. No significant changes in metabolic parameters were observed during CoQ10 supplementation. The treatment was well tolerated and did not interfere with glycemic control, therefore CoQ10 may be used as adjunctive therapy in patients with associated cardiovascular diseases.
